Try GOLD - Free
MTal unveils India's historic $464M medtech FDI leap
BioSpectrum Asia
|BioSpectrum Asia January 2024
India has witnessed a recordbreaking surge of $464 million in foreign investments in medtech in the first 3 quarters, said the Medical Technology Association of India (MTI), which represents leading researchbased medical technology companies with a large footprint in manufacturing and training in India.
-
The government's focus on increasing the ease of doing business in the country, the creation of a globally harmonised regulatory regime for the medical device sector, and initiatives like the National Medical Device Policy (NMDP) 2023 and Promotion of Research and Innovation i
This story is from the BioSpectrum Asia January 2024 edition of BioSpectrum Asia.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM BioSpectrum Asia
BioSpectrum Asia
The Race to Build Singapore's Biotech Unicorns
MIRXES, known for its work in early cancer detection and backed by A*STAR and the National University of Singapore, became Southeast Asia's first biotech unicorn when it listed on the Hong Kong Exchange in 2025.
5 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
"Neuroinflammation is not only a hallmark of Alzheimer's disease but a key pathological feature in other neurodegenerative disorders"
As dementia becomes the leading cause of death in Australia and Alzheimer’s disease continues to affect millions worldwide, the urgency for fundamentally new treatment strategies has never been clearer.
4 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Leprosy Isn't Over: South-East Asia's Unfinished Fight
As we commemorate World Leprosy Day on January 25, the global community is oldest diseases-has not yet been consigned to history.
2 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
"Absence of a widespread infectious disease emergency in 2025 has hindered progress in combating AMR"
After decades of incremental antibiotic innovation, antimicrobial resistance (AMR) is outpacing our ability to respond, and 2026 may mark a breaking point.
5 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
The Strategic Rise of India's Deep-Science Economy
India is emerging as a powerful hub for deep science and biotechnology, driven by favourable geopolitics, a large domestic market, strong pharmaceutical and chemicals infrastructure, and supportive government policies.
4 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Japan strengthening biopharma capabilities
Asia's biopharma landscape is shifting rapidly toward innovation, with countries such as South Korea, Singapore, India, and Taiwan advancing R&D capabilities.
7 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Cancer Diagnosis, Accelerated by AI
Cancer remains a leading cause of death worldwide, with Asia bearing a disproportionate burden.
13 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Beyond Companion Diagnostics: How Biomarkers and Digital Technologies Will Reshape Oncology Care in Asia by 2026
The oncology landscape in Asia stands at a critical juncture.
5 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Pharma M&A set to boom in 2026
After years of unspectacular Mergers and Acquisitions (M&A) activity, 2025 recorded some of the largest pharma deals.
3 mins
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Seeing Opportunity in Ophthalmology
Asia-Pacific is emerging as one of the most active regions for ophthalmology innovation. In recent months, a wave of cross-border partnerships and licensing deals has underscored both the scale of unmet need in eye disease and the region's growing ambition to play a larger role in treatment development. From glaucoma and retinal disorders to dry eye disease and childhood myopia, companies across pharma, biotech, and medtech are increasingly accelerating clinical progress.
6 mins
BioSpectrum Asia Jan 2026
Translate
Change font size